JAK3-IN-9 

JAK3-IN-9 is an orally active JAK3 inhibitor with IC₅₀ value of 1.7 nM. JAK3-IN-9 is highly selective to the JAK3 signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research^[1].

JAK3-IN-9 (compound 11i) shows high selective inhibition of JAK3 with IC₅₀ value of 1.7 nM ^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

JAK3-IN-9 (compound 11i) (Female Lewis rats; 3, 10 and 30 mg/kg; Oral gavage once daily for 20 days) can selectively inhibit JAK3 cytokine signaling in the primary cells^[1].
JAK3-IN-9 (Male DBA1j of 8 to 12-weeks old mice; 1mg/kg, Intravenous injection, Single administration) shows high AUC of 2104 μg/ml, extends t_1/2 to 2.56 h and good oral bioavailability of 48%^[1].
JAK3-IN-9 (30 mg/kg; Oral gavage once daily for 20 days) suppress paw swelling in a dose-dependent manner with ED₅₀ value of 10 mg/kg^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

393.46

C₁₇H₂₃N₅O₄S

1430095-30-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bahekar R, et al. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors. Bioorg Chem. 2020 Jun;99:103851.  [Content Brief]